APA (7th ed.) Citation

D, G., A, F., A, F., & R, S. (2023). Editorial: Ondansetron for patients with IBS-D and bowel-predominant symptoms-authors' reply. Alimentary pharmacology & therapeutics, 57(11), 1337. https://doi.org/10.1111/apt.17496

Chicago Style (17th ed.) Citation

D, Gunn, Ford A, Farrin A, and Spiller R. "Editorial: Ondansetron for Patients with IBS-D and Bowel-predominant Symptoms-authors' Reply." Alimentary Pharmacology & Therapeutics 57, no. 11 (2023): 1337. https://doi.org/10.1111/apt.17496.

MLA (9th ed.) Citation

D, Gunn, et al. "Editorial: Ondansetron for Patients with IBS-D and Bowel-predominant Symptoms-authors' Reply." Alimentary Pharmacology & Therapeutics, vol. 57, no. 11, 2023, p. 1337, https://doi.org/10.1111/apt.17496.